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BACKGROUND
Malignant melanoma (MM) is the most aggressive
skin cancer and the most frequent skin disorder in
Caucasians. MM is associated with aggressive and
progressive disease states, leading to major cancer-
related morbidity and mortality. Recent investigations
identify a new non-angiogenesis-dependent pathway
vasculogenic mimicry (VM), which is considered a
cancer hallmark that can independently facilitate
tumor neovascularization by the formation of fluid-
conducting and vascular endothelial cells. MM cells
undergoing VM can dedifferentiate into numerous
cellular phenotypes and acquire endothelial-like
features, resulting in the formation of the de novo
matrix-rich vascular-like network, such as plasma and
red blood cells. The co-generation of endothelial cells,
channels, laminar structures, and heparin sulfate
proteoglycans are the main pathophysiological
characteristics of VM in human melanoma patients. In
highly aggressive melanoma cells downregulation of
vascular endothelial cadherin and upregulation of ECM
components promote the perfusion of the VM
pathway. We investigated whether mda-9/syntenin, a
pro-metastatic gene, affects VM in MM (Figure 1). The
expression of mda-9/syntenin was modulated using
gain-of-function and loss-of-function strategies to
evaluate its potential role in VM. Downregulation of
mda-9/syntenin in aggressive melanoma cells
decreases VM, while over expressing mda-9/syntenin
in immortalized human melanoma cells increases VM.
These findings shed light on a novel role and molecular
mechanism of action of mda-9/syntenin in VM, which
may contribute significantly to the metastatic
phenotype of these aggressive cancers.
Figure 2. Modification in MDA-9 expression. 
RESULTS
The expression of mda-9/syntenin in normal immortalized
human melanocytes, FM-516, is less in comparison with WM-
35 primary melanoma cells and C8161.9 metastatic melanoma
cells (Figure 2). We determined the intrinsic ability of these
cells to develop vasculogenic mimicry (VM) and observed that
both FM-516 and WM-35 cells did not show VM abilities while
metastatic C8161.9 cells displayed VM. We established clones
of FM-516 cells stably overexpressing mda-9/syntenin and
determined their ability to show VM. Stable overexpression
of mda-9/syntenin in FM-516 cells resulted in an increase in
VM. To further investigate the role of mda-9/syntenin in VM,
we stably silenced mda-9/syntenin expression in C8161.9 cells
and determined their ability to undergo VM. Stably silencing
the expression of mda-9/syntenin in C8161.9 cells resulted in a
decrease in VM, indicating an association between mda-
9/syntenin expression and VM.
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METHODS
• Cell lines and culture conditions: FM-516 SV40 (referred to as FM-
516) cells are normal human melanocytes immortalized using the
SV40 T-antigen. WM-35 are early radial growth phase primary
melanoma cells purchased from American Type Culture Collection
(Manassas, VA). C8161.9 are metastatic melanoma cells (kindly
provided by Dr. Danny R. Welch, University of Kansas Cancer Center).
• Matrigel assay formation: Experimental protocol was performed to
observe VM formation- Preparation of tumor cells and microvascular
endothelial cells, Matrigel preparation, tube formation, image and
data analysis.
• Western Blotting: Cell lysates were collected from the treated cell-
lines. Protein lysates were quantified and equal amounts of proteins 
were treated with specific antibodies.
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Figure 1. Role of MDA-9 in Cancer Biology. 
DISCUSSION
Experimental evidence from our laboratory confirms that
specifically targeting pathways implicated in VM can inhibit
tumor growth. Preclinical studies suggest that specific
compounds affecting components of the described vascular,
embryonic, or hypoxia pathways in tumor cells can inhibit VM
formation in cancer models. VM can provide one of several
sources for a tumor’s blood supply that can directly or
indirectly interact with additional vasculature. Each of the
multiple pathways regulating VM formation warrant serious
scrutiny as potential therapeutic targets and diagnostic
indicator(s) of plasticity, drug resistance, and expression of an
aggressive metastatic phenotype.
Questions to be addressed: Does VM play a significant role in
metastasis? Do tumor cells form their own lymphatic vessels
using processes analogous to VM? And finally, if tumors can
self-vascularize, is an anti-angiogenic approach for shrinking
solid tumors feasible?
